Business
-
Akorn Pharmaceuticals has filed for Chapter 7 bankruptcy and closed all US facilities, including its manufacturing plant in Decatur, IL. A Decatur newspaper, the Herald Review, published a video of Akorn President and CEO Douglas… Read more . . .
-
Oragenics has announced a new license agreement with Inspirevax (formerly Biodextris) for use of Inspirevax’s BDX301 intranasal mucosal adjuvant in Oragenic’s NT-CoV2-1 intranasal COVID-19 vaccine candidate. The company said that the deal includes payments for… Read more . . .
-
According to Vistagen, the US Patent and Trademark Office (USPTO) has granted US Patent 11,419,881 covering the company’s PH80 pherine nasal spray for treatment of migraine until 2040. The company says that “PH80 is an investigational pherine nasal… Read more . . .
-
Aerami Therapeutics announced that it will develop its AER-901 nebulized imatinib for pulmonary hypertension associated with interstitial lung disease (PH-ILD) in addition to pulmonary arterial hypertension (PAH). The FDA granted orphan drug designation to AER-901… Read more . . .
-
According to ARS Pharmaceuticals, Recordati has returned the European marketing rights to ARS-1 epinephrine nasal spray (Neffy) in return for an unspecified amount up front plus future milestone payments connected to European approval and launch… Read more . . .
-
Impel Pharmaceuticals announced that it will cut 16% of its workforce and halt development of INP105 intranasal olanzapine for the treatment of agitation in autism spectrum disorder. The company also said that its Chief Medical Officer,… Read more . . .
-
Israeli biotech BiomX has announced data from the first part of a Phase 1b/2a trial of the company’s BX004 nebulized phage cocktail for the treatment of P. aeruginosa lung infections in cystic fibrosis patients demonstrating a… Read more . . .
-
The non-profit Access to Advanced Health Institute (formerly the Infectious Disease Research Institute) said that it has received an award of up to $3 million for development of a prototype antiviral nasal spray from the… Read more . . .
-
Codagenix said that it has completed a $25 million Series B extension financing, with funds primarily going to support development of its CodaVax-RSV intranasal live attenuated vaccine against respiratory syncytial virus. The FDA recently granted Fast Track… Read more . . .
-
Alveolus Bio has received a 3-year Small Business Innovation Research (SBIR) FastTrack grant worth approximately $2.5 million from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) for development… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland